SCHEMBL3821999

SCHEMBL3821999

CCOC(=O)c1nnn(Cc2ccc(C)cc2)c1C

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 8/20 0.66
LMNA P02545 3/20 0.54
NPC1 O15118 1/20 0.54
TSHR P16473 2/20 0.53
MAPK1 P28482 1/20 0.53
TP53 P04637 1/20 0.52
ALOX12 P18054 1/20 0.52
MAPT P10636 2/20 0.51
ALDH1A1 P00352 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SLC5A1 P13866 1/20 0.46
SLC5A2 P31639 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3823265 0.90 CYP19A1 (0.67) CYP19A1LMNANPC1TP53ALOX12
SCHEMBL15937175 0.89 CYP19A1 (0.57) CYP19A1LMNANPC1TSHRTP53
SCHEMBL15936871 0.89 CYP19A1 (0.74) CYP19A1LMNATSHRMAPK1TP53
SCHEMBL4226447 0.88 CYP19A1 (0.56) CYP19A1TP53ALOX12MAPTALDH1A1
SCHEMBL25333493 0.84 CYP19A1 (0.56) CYP19A1LMNATP53ALOX12MAPT
SCHEMBL17351850 0.82 POLB (0.49) CYP19A1TSHRMAPK1MAPTSMN1; SMN2
SCHEMBL2367846 0.82 HPGD (0.54) CYP19A1TSHRMAPTSMN1; SMN2POLB
SCHEMBL3829134 0.81 NAMPT (0.56) CYP19A1LMNANPC1TSHRMAPK1
SCHEMBL16749151 0.80 CYP19A1 (0.56) CYP19A1LMNANPC1TSHRMAPK1
SCHEMBL15924512 0.80 CYP19A1 (0.56) CYP19A1LMNATSHRTP53ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10316041-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-06-11 US disclosed
US-20180127430-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-05-10 US disclosed
US-9708335-B2 Spiro-lactam NMDA receptor modulators and uses thereof Apytinyx Inc. (US) 2017-07-18 US disclosed
EP-2951185-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2016-12-21 EP disclosed
US-20150368254-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2015-12-24 US disclosed
EP-2096111-A1 PYRAZOLES AND USE THEREOF AS DRUGS Japan Tobacco Inc. (JP) 2009-09-02 EP disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316041-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A CYP19A1 3446/4885LMNA 4431/4885NPC1 1322/4885
US-20180127430-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A CYP19A1 3446/4885LMNA 4431/4885NPC1 1322/4885
US-20150368254-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A CYP19A1 3446/4885LMNA 4431/4885NPC1 1322/4885
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF PYGL, GYS2, G6PC1 CYP19A1 563/4885LMNA 2209/4885NPC1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.